The clinical-stage biopharmaceutical company is focused on cell therapy for autoimmune diseases.The partnership aims to advance the development of novel in vivo chimeric antigen receptor T-cell (CAR-T) therapies for autoimmune diseases, which could significantly enhance the company’s clinical prospects.Cartesian Therapeutics Licenses In Vivo CAR-T Platform With WestGeneWestGene will receive an upfront payment and is eligible for potential development and commercial milestone payments.The collaboration is expected to initiate a clinical trial in the second half of 2026, with clinical data anticipated in the first half of 2027, focusing on patients with myasthenia gravis.RNAC Technical Outlook: Key Levels And MomentumThe stock’s current price of $6.50 is approximately 7.3% below its 20-day simple moving average (SMA) of $7.01, indicating a short-term bearish trend.The moving average convergence divergence (MACD) is currently below its signal line, suggesting that momentum is fading, which could limit the upside unless the stock can regain that baseline.Support and resistance levels are crucial for understanding potential price movements.
Key Resistance: $7.50 — a nearby level where rebounds can stall.
